Broker Tips
Broker tips: Royal Mail, Travis Perkins, Randall and Quilter
Deutsche Bank upgraded Royal Mail to 'buy' from 'hold' on Wednesday, highlighting a "complete change of outlook", as it hiked the price target to 550. 0p from 320. 0p.
Wednesday broker round-up
Standard Chartered: Citigroup downgrades to neutral with a target price of 530p.
Deutsche Bank upgrades Royal Mail, cites ‘complete change of outlook’
Deutsche Bank upgraded Royal Mail to ‘buy’ from ‘hold’ on Wednesday, highlighting a "complete change of outlook", as it hiked the price target to 550p from 320p.
Berenberg ups bid target Signature Aviation to 'hold'
Berenberg upgraded Signature Aviation shares to 'hold' to reflect the recommended offer from Global Infrastructure and the potential for higher bids for the aviation services company.
Berenberg says 'buy' Diploma for earnings momentum
Berenberg upgraded Diploma to 'buy' and reduced Morgan Advanced Materials and Electrocomponents to 'hold' as the broker homed in on earnings momentum for UK industrial groups.
Canaccord raises target price on Travis Perkins
Analysts at Canaccord Genuity raised their target price on builders' merchant and home improvement retailer Travis Perkins from 1,360. 0p to 1,450. 0p on Wednesday after tweaking estimates ahead of the group's full-year results in early March.
Barclays initiates coverage of Randall & Quilter at ‘overweight’
Barclays initiated coverage on shares of Randall & Quilter at ‘overweight’ on Wednesday, arguing the current price does not full reflect the positive fundamentals of the company’s equity story.
Jefferies downgrades Wood Group, warns of likely revisions to revenue forecasts
Jefferies has downgraded Wood Group ahead of potentially "significant" downward revisions to 2021 revenues.
JP Morgan cuts Ryanair to 'neutral' on weaker earnings
JP Morgan cut Ryanair shares to 'neutral' but stayed positive on Wizz Air as the bank reduced earnings forecasts for European budget airlines.
Credit Suisse downgrades Glaxo, highlights near-term challenges
Credit Suisse downgraded GlaxoSmithKline to ‘underperform’ from ‘neutral’ on Wednesday, cutting the price target to 1,400p from 1,580p as it said multiple near-term and strategic challenges make for limited upside versus peers.